Edition:
United Kingdom

Biotechnology & Medical Research

Idorsia H1 US GAAP Net Loss At CHF 232 Mln

July 23 (Reuters) - IDORSIA LTD ::UNCHANGED GUIDANCE FOR 2019: US GAAP OPERATING EXPENSES OF AROUND CHF 570 MILLION.UNCHANGED GUIDANCE: NON-GAAP OPERATING EXPENSES OF AROUND CHF 530 MILLION.US GAAP NET LOSS IN FIRST HALF OF 2019 AMOUNTED TO CHF 232 MILLION COMPARED TO CHF 159 MILLION FOR FIRST HALF...

6:04am BST

Regeneus Announces Positive Preclinical Trial Results For Progenza

July 23 (Reuters) - Regeneus Ltd ::ANNOUNCES POSITIVE PRECLINICAL TRIAL RESULTS FOR PROGENZA IN TREATING NEUROPATHIC PAIN.

12:51am BST

Ra Pharmac Intends To Offer And Sell $100 Mln Of Its Common Stock In Underwritten Public Offering

July 22 (Reuters) - Ra Pharmaceuticals Inc ::RA PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.RA PHARMACEUTICALS INC - INTENDS TO OFFER AND SELL $100 MILLION OF ITS COMMON STOCK IN UNDERWRITTEN PUBLIC OFFERING.RA PHARMACEUTICALS - TO USE PROCEEDS FROM OFFERING TO FUND...

Monday, 22 Jul 2019

Protalix Biotherapeutics Inc - On July 22, Yossi Maimon Notified Of His Resignation As VP And CFO

July 22 (Reuters) - Protalix Biotherapeutics Inc ::PROTALIX BIOTHERAPEUTICS INC - ON JULY 22, YOSSI MAIMON NOTIFIED OF HIS RESIGNATION AS VP AND CFO - SEC FILING.PROTALIX BIOTHERAPEUTICS INC - CO INTENDS TO APPOINT A NEW CHIEF FINANCIAL OFFICER SOON.

Monday, 22 Jul 2019

Expansion & New Markets

Markets

  • Sectors
  • Europe
  • U.S.
  • Asia

Sector Summary

Upcoming Events

No related earnings announcements are currently scheduled within the next 7 days.